-
"Parkinson's disease drugs" cross-border "type 1 diabetes" treatment? Bromocriptine has shown therapeutic potential to improve blood pressure and aortic stiffness
Time of Update: 2023-01-01
In this study, investigators assessed the effects of bromocriptine on blood pressure and aortic sclerosis in adolescents with type 1 diabetes compared with placebo.
In this study, investigators assessed the effects of bromocriptine on blood pressure and aortic sclerosis in adolescents with type 1 diabetes compared with placebo.
-
Technical Guidelines for the Study of Quality Properties of Chewable Tablets (Chemicals) (Draft for Solicitation of Comments) Released
Time of Update: 2022-10-12
Transferred from: CDE Editor: On September 26, CDE publicly solicited opinions on the "Technical Guidelines for the Study of Quality Properties of Chewable Tablets (Chemicals) (Draft for Comments)" 。
-
Tongli Haiyuan invites you to participate in the 6th IGC Conference on Immune Gene and Cell Therapy
Time of Update: 2022-09-14
August 30-31, 2022 (Tue/Wed) Beijing International Convention Center (8 Beichen East Road, Chaoyang District, Beijing, China) Introduction to the conferenceThe conference will focus on three major sections of cellular immunotherapy, gene therapy and stem cell therapy, with 11 supporters, more than 60 sponsors, and more than 100 heavyweight guests, and the conference will attract more than 1,000 clinical/hospital researchers, drug developers, industrial managers and other professional audiences in the industry.
-
Collects large varieties of omeprazole enteric-coated tablets, which are converted from prescription drugs to over-the-counter drugs
Time of Update: 2022-09-06
The announcement states: According to the provisions of the Measures for the Classification and Administration of Prescription Drugs and Over-the-Counter Drugs (Trial Implementation) (formerly Order No. 10 of the State Drug Administration), after the State Drug Administration organized demonstration and review, omeprazole enteric-coated tablets were converted from prescription drugs to over-the-counter drugs.
-
Boehringer Ingelheim develops novel therapy to delay lung function decline in patients with idiopathic pulmonary fibrosis
Time of Update: 2022-08-15
BI 1015550 is a novel phosphodiesterase 4B (PDE4B) inhibitor whose 12-week clinical trial data showed great potential to delay the rate of lung function decline in patients with idiopathic pulmonary fibrosis (IPF) .
-
21 provinces have clarified the implementation time of special centralized insulin collection (with national situation
Time of Update: 2022-08-15
According to the previous schedule, the results of the sixth batch of special centralized procurement of national insulin will be implemented in May 2022. At present, the first-year agreement procure
-
Henan announced the sales of the top 100 pharmaceutical companies in the first quarter: Hengrui, Qilu, Chia Tai Tianqing
Time of Update: 2022-05-16
01 The ranking has changed, and domestic top pharmaceutical companies have an advantage01 The ranking has changed, and domestic top pharmaceutical companies have an advantageOn April 26, the Henan Provincial Public Resource Trading Center issued the "Notice on Publicizing the Province's Online Drug Transactions in the First Quarter of 2022" (hereinafter referred to as the "Notice") .
-
TOP5 neuroleptic drug Lonno Pharma risperidone oral solution is about to be approved
Time of Update: 2022-05-02
Figure 2: Sales of risperidone oral solution (unit: ten thousand yuan) Source: Terminal competition pattern of public medical institutions in China The sales of risperidone oral solution in China's public medical institutions have steadily increased in recent years.
-
Wanchun Pharmaceutical’s rejection of new drug listing, will Hengrui be implicated in the development of new drugs, will it be a “point of no return
Time of Update: 2022-01-12
Can Hengrui break through the “nine deaths and a lifetime” of new drug research and development?Wanchun Pharmaceutical’s core product Punablin was rejected from listing in the United States, plummeting 60%, and its market value fell to less than US$200 million .
-
A pharmacy sells inferior drugs without fines of 100,000
Time of Update: 2022-01-01
Based on the above facts, in accordance with the relevant penal provisions of the "Regulations on the Implementation of the Drug Administration Law", the regulatory authorities impose the following penalties on pharmacies:Ordered to correct relevant illegal acts, and confiscated 55 yuan of illegal gains .
-
Boehringer Ingelheim's first-in-class immune drug Spesolimab submitted a marketing application in China for the treatment of generalized pustular psoriasis
Time of Update: 2021-12-09
Shanghai, October 26, 2021/PRNewswire/ - On October 25, 2021, Boehringer Ingelheim announced that it has formally submitted a listing application for the new immune drug Spesolimab to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration , Used to treat the onset of generalized pustular psoriasis (GPP) .
-
Shiyao exerts strength, 14 new class 1 drugs are coming intensively this year
Time of Update: 2021-11-15
On October 26, CSPC Zhongqi Pharmaceutical's clinical application for SYHX2001 tablets submitted as a new drug category 1 was accepted by the CDE, and the product was declared for clinical use in China for the first time .
-
With favorable policies, the health of the pharmaceutical retail industry will continue to improve
Time of Update: 2021-10-01
However, it should be noted that under the background of policy guidance, health industry upgrades, and changes in consumer demand that promote the acceleration of the development of the pharmaceutical retail industry, this market is actually facing many new challenges .
-
Black technology
Time of Update: 2021-09-30
H. Ceren Ates, FIT Freiburg Interactive Materials and Bioinspiration Technology Center and Professor Wilfried Weber, Professor of Synthetic Biology and CIBSS Excellence Cluster-a lecture team of the Center for Integrated Biosignal Research Member, based on synthetic protein that reacts to antibiotics, resulting in electrical changes .
-
Takeda's new oral small molecule drug mobocertinib capsule is included in priority review in China
Time of Update: 2021-08-15
It was awarded a breakthrough therapy designation by the FDA in April 2020 for the treatment of patients with EGFR Exon20 insertion mutation NSCLC who had disease progression during or after platinum-containing chemotherapy .
